Biological Products, (No Diagnostic Substances) Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Biological Products, (No Diagnostic Substances)
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2020-01-16 | WINT | Windtree Therapeutics Inc /de/ | Huang James | Dir, 10% | P - Purchase | $4.18 | +2,058 | 6,416,318 | 0% | +$8,609 | |||||
| D | 2020-01-16 | HARP | Harpoon Therapeutics, Inc. | Sacks Natalie | Chief Medical Officer | S - Sale+OE | $14.94 | -1,521 | 45,754 | -3% | -$22,725 | |||||
| D | 2020-01-16 | PTE | Polarityte, Inc. | Lough Denver | Prior Director and Officer, 10% | S - Sale+OE | $4.17 | -10,000 | 0 | -100% | -$41,700 | |||||
2020-01-17 | AXLA | Axcella Health Inc. | Sohn Catherine A. | Dir | P - Purchase | $4.87 | +1,000 | 1,000 | New | +$4,870 | ||||||
| D | 2020-01-17 | RGNX | Regenxbio Inc. | Simpson Curran | SVP, Product Development, CTO | S - Sale+OE | $50.00 | -5,922 | 23,148 | -20% | -$296,100 | |||||
2020-01-17 | RGNX | Regenxbio Inc. | Vasista Vittal | CFO | S - Sale | $50.00 | -2,394 | 222,321 | -1% | -$119,700 | ||||||
| D | 2020-01-17 | RGNX | Regenxbio Inc. | Hayden Donald J Jr | Dir | S - Sale+OE | $50.01 | -3,200 | 0 | -100% | -$160,032 | |||||
2020-01-17 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale | $20.96 | -11,046 | 24,755,816 | 0% | -$231,524 | ||||||
| DM | 2020-01-15 | ADPT | Adaptive Biotechnologies Corp | Robins Harlan S | Chief Scientific Officer | S - Sale+OE | $28.77 | -11,100 | 870,679 | -1% | -$319,329 | |||||
| M | 2020-01-15 | TWST | Twist Bioscience Corp | Banyai William | See Remarks | S - Sale | $22.77 | -22,000 | 622,033 | -3% | -$500,850 | |||||
2020-01-15 | ALEC | Alector, Inc. | Paul Robert | Chief Medical Officer | S - Sale | $18.67 | -10,000 | 273,719 | -4% | -$186,700 | ||||||
| D | 2020-01-15 | MNTA | Momenta Pharmaceuticals Inc | Beltramello Jo Ann | Chief HR, Inf. Officer | S - Sale+OE | $28.58 | -43,194 | 87,594 | -33% | -$1,234,544 | |||||
| D | 2020-01-15 | MNTA | Momenta Pharmaceuticals Inc | Manning Anthony M. | Chief Scientific Officer | S - Sale+OE | $28.44 | -29,114 | 5,443 | -84% | -$828,002 | |||||
| D | 2020-01-15 | CHRS | Coherus Biosciences, Inc. | Viret Jean-Frederic | CFO | S - Sale+OE | $19.85 | -6,318 | 46,841 | -12% | -$125,424 | |||||
| D | 2020-01-14 | MNTA | Momenta Pharmaceuticals Inc | Beltramello Jo Ann | Chief HR, Inf. Officer | S - Sale+OE | $23.42 | -122,589 | 88,530 | -58% | -$2,870,761 | |||||
| D | 2020-01-14 | MNTA | Momenta Pharmaceuticals Inc | Fier Ian | Chief Mfg, Program Officer | S - Sale+OE | $23.58 | -87,703 | 1,182 | -99% | -$2,068,147 | |||||
| D | 2020-01-14 | MNTA | Momenta Pharmaceuticals Inc | Stoner Elizabeth | Dir | S - Sale+OE | $25.00 | -4,236 | 35,509 | -11% | -$105,900 | |||||
| D | 2020-01-14 | RGNX | Regenxbio Inc. | Hayden Donald J Jr | Dir | S - Sale+OE | $45.60 | -30,000 | 0 | -100% | -$1,368,000 | |||||
2020-01-14 | LJPC | La Jolla Pharmaceutical Co | Wellinghoff Darryl | Chief Commercial Officer | P - Purchase | $8.23 | +3,000 | 6,545 | +85% | +$24,677 | ||||||
2020-01-14 | ADAP | Adaptimmune Therapeutics Plc | Norry Elliot | Chief Medical Officer | S - Sale | $5.13 | -911 | 1,326 | -41% | -$4,678 | ||||||
2020-01-14 | ADAP | Adaptimmune Therapeutics Plc | Bertrand William C Jr | COO | S - Sale | $5.13 | -2,397 | 3,605 | -40% | -$12,308 | ||||||
2020-01-13 | ADAP | Adaptimmune Therapeutics Plc | Tayton-Martin Helen Katrina | Chief Business Officer | S - Sale | $4.50 | -100,000 | 0 | -100% | -$450,000 | ||||||
2020-01-14 | ADAP | Adaptimmune Therapeutics Plc | Lunger John | Chief Patient Supply Officer | S - Sale | $5.13 | -1,144 | 1,681 | -40% | -$5,874 | ||||||
2020-01-14 | ADAP | Adaptimmune Therapeutics Plc | Rawcliffe Adrian | CEO | S - Sale | $5.13 | -3,236 | 3,166 | -51% | -$16,616 | ||||||
2020-01-13 | ADAP | Adaptimmune Therapeutics Plc | Noble James | Dir | S - Sale | $4.67 | -300,000 | 0 | -100% | -$1,400,000 | ||||||
| A | 2020-01-07 | IDRA | Idera Pharmaceuticals, Inc. | Yingling Jonathan Michael | Chief Scientific Officer | S - Sale | $1.78 | -1,742 | 16,358 | -10% | -$3,101 | |||||
| A | 2020-01-07 | IDRA | Idera Pharmaceuticals, Inc. | Lim Bryant David | SVP, GC | S - Sale | $1.78 | -1,603 | 21,240 | -7% | -$2,854 | |||||
| A | 2020-01-07 | IDRA | Idera Pharmaceuticals, Inc. | Fletcher Robert C. | SVP, Bus. Dev., Strategy | S - Sale | $1.78 | -1,615 | 16,485 | -9% | -$2,875 | |||||
2020-01-13 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale | $19.14 | -10,000 | 2,090,646 | 0% | -$191,400 | ||||||
| A | 2020-01-07 | IDRA | Idera Pharmaceuticals, Inc. | Kirby John J. | CFO | S - Sale | $1.78 | -911 | 16,437 | -5% | -$1,622 | |||||
| A | 2020-01-07 | IDRA | Idera Pharmaceuticals, Inc. | Milano Vincent | Pres, CEO | S - Sale | $1.78 | -3,006 | 86,560 | -3% | -$5,352 | |||||
| D | 2020-01-10 | BLUE | Bluebird Bio, Inc. | Gregory Philip D | Chief Scientific Officer | S - Sale+OE | $94.03 | -600 | 24,708 | -2% | -$56,416 | |||||
2020-01-10 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale | $20.24 | -16,482 | 16,007,195 | 0% | -$333,582 | ||||||
| M | 2020-01-10 | MRNA | Moderna, Inc. | Kania Edwin M Jr | 10% | S - Sale | $20.26 | -475,000 | 23,847 | -95% | -$9,623,813 | |||||
| M | 2020-01-09 | LJPC | La Jolla Pharmaceutical Co | Tang Kevin C | Dir, 10% | P - Purchase | $5.87 | +2,971,682 | 7,910,575 | +60% | +$17,434,468 | |||||
| DM | 2020-01-09 | NSTG | Nanostring Technologies Inc | Ghesquiere David W. | SVP, Corporate, Business Dev | S - Sale+OE | $29.07 | -19,579 | 54,169 | -27% | -$569,144 | |||||
2020-01-09 | ALEC | Alector, Inc. | Orbimed Advisors LLC | 10% | S - Sale | $19.50 | -379,997 | 38,808 | -91% | -$7,409,942 | ||||||
2020-01-10 | EIGR | Eiger Biopharmaceuticals, Inc. | Dietz Thomas John | Dir | P - Purchase | $13.94 | +4,000 | 24,000 | +20% | +$55,760 | ||||||
2020-01-10 | CVM | Cel Sci Corp | Kersten Geert R | CEO | P - Purchase | $7.54 | +6,631 | 1,114,538 | +1% | +$49,998 | ||||||
2020-01-08 | TWST | Twist Bioscience Corp | Weiss Patrick | COO | S - Sale | $21.50 | -4,090 | 99,226 | -4% | -$87,937 | ||||||
| D | 2020-01-08 | SGEN | Seattle Genetics Inc /wa | Siegall Clay B | Pres, CEO | S - Sale+OE | $111.32 | -28,472 | 758,784 | -4% | -$3,169,433 | |||||
| D | 2020-01-08 | ADPT | Adaptive Biotechnologies Corp | Taylor Stacy L | SVP, GC | S - Sale+OE | $30.00 | -662 | 1,300 | -34% | -$19,860 | |||||
| D | 2020-01-08 | ADPT | Adaptive Biotechnologies Corp | Cohen Chad M | CFO | S - Sale+OE | $29.87 | -20,000 | 1,000 | -95% | -$597,400 | |||||
| D | 2020-01-08 | RGNX | Regenxbio Inc. | Vasista Vittal | CFO | S - Sale+OE | $41.75 | -7,500 | 224,715 | -3% | -$313,152 | |||||
2020-01-08 | NBIX | Neurocrine Biosciences Inc | Roberts Eiry | Chief Medical Officer | S - Sale | $111.11 | -2,632 | 5,991 | -31% | -$292,445 | ||||||
| D | 2020-01-08 | FATE | Fate Therapeutics Inc | Valamehr Bahram | Chief Development Officer | S - Sale+OE | $20.69 | -5,700 | 86,058 | -6% | -$117,947 | |||||
| D | 2020-01-08 | FATE | Fate Therapeutics Inc | Tahl Cindy | GC, Secretary | S - Sale+OE | $20.72 | -5,700 | 99,518 | -5% | -$118,085 | |||||
| D | 2020-01-08 | FATE | Fate Therapeutics Inc | Shoemaker Daniel D | Chief Scientific Officer | S - Sale+OE | $20.70 | -5,700 | 143,091 | -4% | -$117,986 | |||||
2020-01-07 | JNCE | Jounce Therapeutics, Inc. | Drapkin Kimberlee C | CFO, Treasurer | S - Sale | $7.78 | -2,624 | 44,390 | -6% | -$20,415 | ||||||
2020-01-07 | JNCE | Jounce Therapeutics, Inc. | Trehu Elizabeth | Chief Medical Officer | S - Sale | $7.78 | -2,624 | 56,565 | -4% | -$20,415 | ||||||
2020-01-07 | JNCE | Jounce Therapeutics, Inc. | Murray Richard /ca/ | CEO, Pres | S - Sale | $7.78 | -7,150 | 87,360 | -8% | -$55,627 | ||||||
2020-01-07 | JNCE | Jounce Therapeutics, Inc. | Cole Hugh M | Chief Business Officer | S - Sale | $7.78 | -2,624 | 33,590 | -7% | -$20,415 | ||||||
2020-01-07 | IDRA | Idera Pharmaceuticals, Inc. | Yingling Jonathan Michael | Chief Scientific Officer | S - Sale | $1.78 | -1,742 | 16,358 | -10% | -$3,101 | ||||||
2020-01-07 | IDRA | Idera Pharmaceuticals, Inc. | Milano Vincent | Pres, CEO | S - Sale | $1.78 | -3,006 | 86,560 | -3% | -$5,352 | ||||||
2020-01-07 | IDRA | Idera Pharmaceuticals, Inc. | Kirby John J. | CFO | S - Sale | $1.78 | -911 | 16,437 | -5% | -$1,622 | ||||||
2020-01-07 | IDRA | Idera Pharmaceuticals, Inc. | Fletcher Robert C. | SVP, Bus. Dev., Strategy | S - Sale | $1.78 | -1,615 | 16,485 | -9% | -$2,875 | ||||||
2020-01-07 | IDRA | Idera Pharmaceuticals, Inc. | Lim Bryant David | SVP, GC | S - Sale | $1.78 | -1,603 | 21,240 | -7% | -$2,854 | ||||||
2020-01-07 | BLUE | Bluebird Bio, Inc. | Smith-Farrell Joanne | Chief Business Officer | S - Sale | $89.97 | -408 | 11,976 | -3% | -$36,708 | ||||||
2020-01-07 | BLUE | Bluebird Bio, Inc. | Wentworth Kory James | Principal Accounting Officer | S - Sale | $89.97 | -223 | 6,308 | -3% | -$20,064 | ||||||
2020-01-07 | BLUE | Bluebird Bio, Inc. | Finger Alison Cecily | Chief Commercial Officer | S - Sale | $89.97 | -1,049 | 18,148 | -5% | -$94,380 | ||||||
2020-01-07 | BLUE | Bluebird Bio, Inc. | Cole Jason | COO and | S - Sale | $89.97 | -1,957 | 25,049 | -7% | -$176,074 | ||||||
2020-01-07 | BLUE | Bluebird Bio, Inc. | Davidson David | Chief Medical Officer | S - Sale | $89.97 | -3,297 | 28,319 | -10% | -$296,635 | ||||||
2020-01-07 | BLUE | Bluebird Bio, Inc. | Gregory Philip D | Chief Scientific Officer | S - Sale | $89.97 | -4,134 | 24,708 | -14% | -$371,941 | ||||||
2020-01-07 | BLUE | Bluebird Bio, Inc. | Leschly Nick | Pres, CEO | S - Sale | $89.97 | -10,163 | 225,411 | -4% | -$914,377 | ||||||
2020-01-06 | BLUE | Bluebird Bio, Inc. | Gregory Philip D | Chief Scientific Officer | S - Sale | $86.66 | -250 | 28,842 | -1% | -$21,665 | ||||||
2020-01-06 | JNCE | Jounce Therapeutics, Inc. | Higgons John Duncan | Dir | S - Sale | $8.11 | -1,500 | 12,013 | -11% | -$12,165 | ||||||
| D | 2020-01-06 | TECH | Bio-Techne Corp | Kummeth Charles R. | CEO | S - Sale+OE | $217.28 | -10,276 | 130,189 | -7% | -$2,232,769 | |||||
| AD | 2019-12-31 | ADPT | Adaptive Biotechnologies Corp | Dobmeier Eric | Dir | S - Sale+OE | $30.00 | -5,000 | 0 | -100% | -$150,000 | |||||
| AD | 2019-12-26 | ADPT | Adaptive Biotechnologies Corp | Dobmeier Eric | Dir | S - Sale+OE | $29.29 | -15,000 | 0 | -100% | -$439,351 | |||||
| D | 2020-01-06 | ADPT | Adaptive Biotechnologies Corp | Hill Nancy Louise | SVP, Operations | S - Sale+OE | $29.14 | -60,000 | 11,200 | -84% | -$1,748,400 | |||||
2020-01-06 | ADAP | Adaptimmune Therapeutics Plc | Lunger John | Chief Patient Supply Officer | S - Sale | $1.20 | -1,148 | 1,677 | -41% | -$1,378 | ||||||
2020-01-06 | ADAP | Adaptimmune Therapeutics Plc | Bertrand William C Jr | COO | S - Sale | $1.20 | -3,731 | 5,632 | -40% | -$4,477 | ||||||
2020-01-06 | ADAP | Adaptimmune Therapeutics Plc | Rawcliffe Adrian | CEO | S - Sale | $1.20 | -5,900 | 5,804 | -50% | -$7,080 | ||||||
2020-01-03 | BLUE | Bluebird Bio, Inc. | Finger Alison Cecily | Chief Commercial Officer | S - Sale | $84.96 | -517 | 19,197 | -3% | -$43,924 | ||||||
| D | 2020-01-02 | HARP | Harpoon Therapeutics, Inc. | Wesche Holger | Chief Scientific Officer | S - Sale+OE | $14.40 | -10,000 | 52,669 | -16% | -$143,987 | |||||
| D | 2020-01-02 | HARP | Harpoon Therapeutics, Inc. | Sacks Natalie | Chief Medical Officer | S - Sale+OE | $14.18 | -5,826 | 45,754 | -11% | -$82,600 | |||||
| D | 2020-01-03 | GILD | Gilead Sciences Inc | Pletcher Brett A | EVP,Corp Affairs, GC | S - Sale+OE | $64.63 | -2,950 | 17,064 | -15% | -$190,659 | |||||
2020-01-02 | ORTX | Orchard Therapeutics Plc | Fmr LLC | See Remark 1, 10% | S - Sale | $13.46 | -28,474 | 12,244,590 | 0% | -$383,372 | ||||||
2020-01-02 | CDTX | Cidara Therapeutics, Inc. | Oien Jessica | GC, Secretary | S - Sale | $3.86 | -834 | 6,965 | -11% | -$3,219 | ||||||
2020-01-03 | CDTX | Cidara Therapeutics, Inc. | Abdollahian Neil | Chief Business Officer | S - Sale | $3.42 | -2,340 | 51,248 | -4% | -$8,003 | ||||||
2020-01-03 | CDTX | Cidara Therapeutics, Inc. | Daruwala Paul | COO | S - Sale | $3.42 | -2,340 | 53,532 | -4% | -$8,003 | ||||||
2020-01-02 | OCX | Oncocyte Corp | Lineage Cell Therapeutics, Inc. | Previous 10% Owner | S - Sale | $2.16 | -2,383,090 | 6,041,154 | -28% | -$5,137,942 | ||||||
| DM | 2020-01-02 | TECH | Bio-Techne Corp | Kummeth Charles R. | CEO | S - Sale+OE | $218.29 | -27,842 | 130,189 | -18% | -$6,077,781 | |||||
| M | 2020-01-02 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale | $19.21 | -16,160 | 7,568,874 | 0% | -$310,397 | |||||
| M | 2020-01-02 | XLRN | Acceleron Pharma Inc | Veness Adam M | VP, GC, Sec. | S - Sale | $51.76 | -1,309 | 14,792 | -8% | -$67,754 | |||||
2020-01-03 | XLRN | Acceleron Pharma Inc | Kango Sujay | SVP, Chief Commercial Officer | S - Sale | $51.37 | -480 | 9,570 | -5% | -$24,657 | ||||||
2020-01-02 | XLRN | Acceleron Pharma Inc | Quisel John D | EVP, Chief Business Officer | S - Sale | $52.52 | -5,842 | 53,316 | -10% | -$306,806 | ||||||
2020-01-02 | XLRN | Acceleron Pharma Inc | McLaughlin Kevin F | SVP, CFO, Treasurer | S - Sale | $52.50 | -5,579 | 4,847 | -54% | -$292,923 | ||||||
2020-01-03 | XLRN | Acceleron Pharma Inc | Dable Habib J | CEO, Pres | S - Sale | $51.24 | -3,732 | 67,151 | -5% | -$191,230 | ||||||
2019-12-31 | WINT | Windtree Therapeutics Inc /de/ | Huang James | Dir, 10% | P - Purchase | $4.05 | +15,442 | 6,414,260 | 0% | +$62,525 | ||||||
| D | 2019-12-31 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres | S - Sale+OE | $30.00 | -40,000 | 0 | -100% | -$1,200,000 | |||||
2019-12-27 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale | $19.53 | -11,046 | 24,804,493 | 0% | -$215,728 | ||||||
2019-12-31 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $3.67 | +4,000 | 163,411 | +3% | +$14,676 | ||||||
| D | 2019-12-30 | FATE | Fate Therapeutics Inc | Shoemaker Daniel D | Chief Scientific Officer | S - Sale+OE | $19.50 | -25,000 | 123,791 | -17% | -$487,427 | |||||
| M | 2019-12-27 | WINT | Windtree Therapeutics Inc /de/ | Huang James | Dir, 10% | P - Purchase | $3.74 | +5,000 | 6,398,818 | 0% | +$18,724 | |||||
| DM | 2019-12-27 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres | S - Sale+OE | $28.98 | -135,000 | 0 | -100% | -$3,912,585 | |||||
2019-12-27 | HARP | Harpoon Therapeutics, Inc. | Baeuerle Patrick | Dir | S - Sale | $15.98 | -87,379 | 262,136 | -25% | -$1,396,281 | ||||||
2019-12-26 | AGTC | Applied Genetic Technologies Corp | Krol Patrick Johan Hendrik | 10% | S - Sale | $5.24 | -81,162 | 1,805,761 | -4% | -$425,289 | ||||||
2019-12-26 | STRO | Sutro Biopharma, Inc. | Hallam Trevor | Chief Science Officer | S - Sale | $11.08 | -975 | 24,590 | -4% | -$10,802 | ||||||
| D | 2019-12-24 | MNTA | Momenta Pharmaceuticals Inc | Fier Ian | Chief Mfg, Program Officer | S - Sale+OE | $20.00 | -39,133 | 1,182 | -97% | -$782,660 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |